{
    "clinical_study": {
        "@rank": "85590", 
        "acronym": "DM-SAHS", 
        "arm_group": [
            {
                "arm_group_label": "lifestyle and diabetes treatment", 
                "arm_group_type": "No Intervention", 
                "description": "Counseil about lifestyle and current diabetes treatment"
            }, 
            {
                "arm_group_label": "CPAP nasal treatment", 
                "arm_group_type": "Experimental", 
                "description": "Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device"
            }
        ], 
        "brief_summary": {
            "textblock": "Aim: To assess if six months of treatment with CPAP associated with conventional drug\n      therapy, contribute to improved glycemic control in patients with type 2 diabetes and sleep\n      apnea-hypopnea syndrome SAHS)"
        }, 
        "brief_title": "CPAP in Diabetes Type 2 Patients With Sleep Apnea", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Sleep Apnea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Diabetes Mellitus", 
                "Sleep Apnea Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Main objective:\n\n      To assess the effect of 6 months of CPAP treatment associated with conventional drug therapy\n      on glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome\n      (SAHS)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects 18 to 75 years old; diagnosis of type 2 diabetes mellitus; treatment with\n             diet;  oral antidiabetics or insulin stable in the last month; levels of HbA1c> 7.5%\n             (if not supported clinic two controls to confirm with a difference not exceeding\n             0.5%); overweight or obese (BMI \u2265 25 kg/m2)\n\n        Exclusion Criteria:\n\n          -  professional drivers, risk profession or respiratory failure; excessive daytime\n             sleepiness is very high (Epworth scale> 18); morbid obesity (BMI> 40 kg/m2); CPAP\n             treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801150", 
            "org_study_id": "HULP-DM-SAHS-2012"
        }, 
        "intervention": {
            "arm_group_label": "CPAP nasal treatment", 
            "description": "Treatment with titred CPAP nasal during the nighttime", 
            "intervention_name": "CPAP nasal treatment", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Apnea- hypopnea Syndrome", 
            "Glycemic control", 
            "Prevalence", 
            "SAHS", 
            "life quality"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "contact": {
                "email": "fgr01@gmail.com", 
                "last_name": "Francisco Garc\u00eda Rio", 
                "phone": "917277253"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "Hospital Universitario La Paz- IdiPaz"
            }, 
            "investigator": {
                "last_name": "Elisabet Mart\u00ednez- Cer\u00f3n", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect Of Nasal CPAP On Glycemic Control In Patients With Poorly Controlled Type 2 Diabetes And Sleep Apnea-Hypopnea Syndrome", 
        "other_outcome": [
            {
                "description": "Analyze the impact of additional treatment with CPAP on serum lipids and C-reactive protein concentration in patients with type 2 diabetes and SAHS", 
                "measure": "Impact of CPAP on glycemic control", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Establish the impact of additional treatment with CPAP on quality of life related to health of patients with type 2 diabetes and SAHS.", 
                "measure": "Quality of life after CPAP", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To evaluate the effect of CPAP on inflammatory cytokines, biomarkers of oxidative stress, sympathetic tone and intake regulating hormones in patients with type 2 diabetes and SAHS.", 
                "measure": "Inflammatory markers after CPAP", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Relate the CPAP-induced changes in the concentration of HbA1c and HOMA index with changes produced in the basal inflammatory reaction, oxidative stress, sympathetic activity and intake regulatory hormones.\nIdentify the subset of patients with poorly controlled type 2 diabetes and SAHS in the six months of treatment with CPAP achieve a more pronounced reduction in HbA1c.", 
                "measure": "Endocrine control with CPAP treatment", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To estimate the influence of the distribution of body mass and daily physical activity of patients with type 2 diabetes and SAHS on the metabolic response to treatment with CPAP.", 
                "measure": "Influence of body distribution and activity on metabolic control", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "martienzcerone@gmail.com", 
            "last_name": "Elisabet Mart\u00ednez", 
            "phone": "917277253"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario La Paz, IdiPAZ", 
                "last_name": "Francisco Garcia-Rio, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital Universitario La Paz, IdiPAZ", 
                "last_name": "Elizabet Mart\u00ednez-Cer\u00f3n, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Son Espasses", 
                "last_name": "Alberto Alonso-Fern\u00e1ndez, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the effect of 6 months of CPAP therapy and conventional treatment on glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome (SAHS)", 
            "measure": "Glycemic control", 
            "safety_issue": "No", 
            "time_frame": "Six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801150"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario La Paz", 
            "investigator_full_name": "Francisco Garcia-Rio", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": ". Determine the medium term additional effect of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.", 
            "measure": "To determine additional effects of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}